|
1) 小嶋哲人. 抗凝固薬の歴史とXa阻害薬の開発目的を探る. In: 池田康夫, 坂田洋一, 丸山征郎, 編. Xa阻害薬のすべて. 東京: 先端医学社; 2007. p. 68-75
|
|
|
|
|
2) McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916; 41: 250
|
|
|
|
|
|
3) Weitz JI, Bates SM. New anticoagulants. J Thoromb Haemost. 2005; 3: 1843-53
|
|
|
|
|
|
4) Oosta GM, Gardner WT, Beeler DL, et al. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci U S A. 1981; 78: 829-33
|
|
|
|
|
5) Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun. 1983; 116: 492-9
|
|
|
|
|
|
6) Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001; 345: 1298-304
|
|
|
|
|
|
7) Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345: 1305-10
|
|
|
|
|
|
8) Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359: 1715-20
|
|
|
|
|
|
9) Turpie AG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux vs. postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002; 359: 1721-6
|
|
|
|
|
|
10) Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of four randomized double-blind studies. Arch Intern Med. 2002; 162: 1833-40
|
|
|
|
|
|
11) Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents— the selective factor Xa inhibitors. Cardiovasc. Drug Rev. 2002; 20: 37-52
|
|
|
|
|
|
12) Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of HIT. In: Warkentin TE, Greinacher A, (editors). Heparin-induced thrombocytopenia. 2nd ed. New York: Marcel Dekker; 2001. p. 167-87
|
|
|
|
|
|
13) Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 1997; 8: 114-7
|
|
|
|
|
|
14) Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008; 28: 380-6
|
|
|
|
|
|
15) Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008; 25: 52-60
|
|
|
|
|
|
16) Gerotziafas GT, Samama MM. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des. 2005; 11: 3855-76
|
|
|
|
|
|
17) van Gogh investigators, Buller HR, Cohen AT, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007; 357: 1094-104
|
|
|
|
|
|
18) van Gogh Investigators, Buller HR, Cohen AT, et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007; 357: 1105-12
|
|
|
|
|
|
19) Amadeus Investigators. Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008; 371: 315-21
|
|
|
|
|
|
20) Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007; 98: 883-8
|
|
|
|
|
|
21) Bauer KA. New anticoagulants. Hematology. Am Soc Hematol Educ Program. 2006; 450-6
|
|
|
|
|
|
22) Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370: 949-56
|
|
|
|
|
|
23) Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5: 2178-85
|
|
|
|
|
|
24) Ginsberg JS, Davidson BL, Comp PC, et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. in press
|
|
|
|
|